Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 268

1.

Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.

Faust-Socher A, Duff-Canning S, Grabovsky A, Armstrong MJ, Rothberg B, Eslinger PJ, Meaney CA, Schneider RB, Tang-Wai DF, Fox SH, Zadikoff C, Kennedy N, Chou KL, Persad C, Litvan I, Mast BT, Gerstenecker AT, Weintraub S, Reginold W, Marras C.

Dement Geriatr Cogn Disord. 2019 Jul 17:1-11. doi: 10.1159/000496454. [Epub ahead of print]

PMID:
31315127
2.

Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability.

Shoeibi A, Litvan I, Tolosa E, Ser TD, Lee E; TAUROS Investigators.

Parkinsonism Relat Disord. 2019 Jul 9. pii: S1353-8020(19)30300-1. doi: 10.1016/j.parkreldis.2019.07.010. [Epub ahead of print]

PMID:
31307919
3.

Factor Analysis of the Apathy Scale in Parkinson's Disease.

Lopez FV, Eglit GML, Schiehser DM, Pirogovsky-Turk E, Litvan I, Lessig S, Filoteo JV.

Mov Disord Clin Pract. 2019 Apr 30;6(5):379-386. doi: 10.1002/mdc3.12767. eCollection 2019 Jun.

PMID:
31286007
4.

Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration.

Staffaroni AM, Cobigo Y, Goh SM, Kornak J, Bajorek L, Chiang K, Appleby B, Bove J, Bordelon Y, Brannelly P, Brushaber D, Caso C, Coppola G, Dever R, Dheel C, Dickerson BC, Dickinson S, Dominguez S, Domoto-Reilly K, Faber K, Ferrall J, Fields JA, Fishman A, Fong J, Foroud T, Forsberg LK, Gavrilova R, Gearhart D, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Haley D, Heuer HW, Hsiung GY, Huey ED, Irwin DJ, Jones DT, Jones L, Kantarci K, Karydas A, Kaufer DI, Kerwin DR, Knopman DS, Kraft R, Kramer JH, Kremers WK, Kukull WA, Litvan I, Ljubenkov PA, Lucente D, Lungu C, Mackenzie IR, Maldonado M, Manoochehri M, McGinnis SM, McKinley E, Mendez MF, Miller BL, Multani N, Onyike C, Padmanabhan J, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin KP, Rascovsky K, Roberson ED, Rogalski E, Sengdy P, Shaw LM, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski JQ, Weintraub S, Wang P, Wong B, Wszolek Z, Boxer AL, Boeve BF, Rosen HJ; ARTFL/LEFFTDS consortium.

Alzheimers Dement. 2019 Jul 1. pii: S1552-5260(19)30111-6. doi: 10.1016/j.jalz.2019.04.007. [Epub ahead of print]

5.

The role of dispositional mindfulness in a stress-health pathway among Parkinson's disease patients and caregiving partners.

Hicks A, Phillips K, Siwik C, Salmon P, Litvan I, Jablonski ME, Filoteo JV, Kayser K, Sephton SE.

Qual Life Res. 2019 Jun 14. doi: 10.1007/s11136-019-02217-6. [Epub ahead of print]

PMID:
31201728
6.

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.

Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, Honig LS, Tuite P, McFarland NR, O'Suilleabhain P, Xie T, Tirucherai GS, Bechtold C, Bordelon Y, Geldmacher DS, Grossman M, Isaacson S, Zesiewicz T, Olsson T, Muralidharan KK, Graham DL, O'Gorman J, Haeberlein SB, Dam T.

Lancet Neurol. 2019 Jun;18(6):549-558. doi: 10.1016/S1474-4422(19)30139-5.

PMID:
31122495
7.

Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.

Staffaroni AM, Bajorek L, Casaletto KB, Cobigo Y, Goh SM, Wolf A, Heuer HW, Elahi FM, Ljubenkov PA, Dever R, Kornak J, Appleby B, Bove J, Bordelon Y, Brannelly P, Brushaber D, Caso C, Coppola G, Dheel C, Dickerson BC, Dickinson S, Dominguez S, Domoto-Reilly K, Faber K, Ferrall J, Fields JA, Fishman A, Fong J, Foroud T, Forsberg LK, Gavrilova R, Gearhart D, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Haley D, Hsiung GY, Huey ED, Irwin DJ, Jones DT, Jones L, Kantarci K, Karydas A, Kaufer DI, Kerwin DR, Knopman DS, Kraft R, Kremers WK, Kukull WA, Litvan I, Lucente D, Lungu C, Mackenzie IR, Maldonado M, Manoochehri M, McGinnis SM, McKinley E, Mendez MF, Miller BL, Multani N, Onyike C, Padmanabhan J, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin KP, Rascovsky K, Roberson ED, Rogalski E, Sengdy P, Shaw LM, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski JQ, Weintraub S, Wang P, Wong B, Wszolek Z, Boxer AL, Boeve BF, Kramer JH, Rosen HJ; ARTFL/LEFFTDS consortium.

Alzheimers Dement. 2019 May 11. pii: S1552-5260(19)30044-5. doi: 10.1016/j.jalz.2019.01.012. [Epub ahead of print]

8.

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol JC, Lang AE, Rowe JB, Höglinger GU; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2019 Mar 18. doi: 10.1002/mds.27666. [Epub ahead of print]

PMID:
30884545
9.

Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings.

Peterson B, Armstrong M, Galasko D, Galvin JE, Goldman J, Irwin D, Paulson H, Kaufer D, Leverenz J, Lunde A, McKeith IG, Siderowf A, Taylor A, Amodeo K, Barrett M, Domoto-Reilly K, Duda J, Gomperts S, Graff-Radford N, Holden S, Honig L, Huddleston D, Lippa C, Litvan I, Manning C, Marder K, Moussa C, Onyike C, Pagan F, Pantelyat A, Pelak V, Poston K, Quinn J, Richard I, Rosenthal LS, Sabbagh M, Scharre D, Sha S, Shill H, Torres-Yaghi Y, Christie T, Graham T, Richards I, Koehler M, Boeve B.

Alzheimers Res Ther. 2019 Mar 13;11(1):23. doi: 10.1186/s13195-019-0476-1.

10.

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.

Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB.

Neurology. 2019 Feb 12;92(7):329-337. doi: 10.1212/WNL.0000000000006926.

PMID:
30745444
11.

End of life planning in parkinsonian diseases.

Gillard DM, Proudfoot JA, Simões RM, Litvan I.

Parkinsonism Relat Disord. 2019 May;62:73-78. doi: 10.1016/j.parkreldis.2019.01.026. Epub 2019 Jan 30.

PMID:
30718221
12.

Risk of Parkinson's disease dementia related to level I MDS PD-MCI.

Hoogland J, Boel JA, de Bie RMA, Schmand BA, Geskus RB, Dalrymple-Alford JC, Marras C, Adler CH, Weintraub D, Junque C, Pedersen KF, Mollenhauer B, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ; MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2019 Mar;34(3):430-435. doi: 10.1002/mds.27617. Epub 2019 Jan 17.

PMID:
30653248
13.

The virtual reality of Parkinson's disease freezing of gait: A systematic review.

Bluett B, Bayram E, Litvan I.

Parkinsonism Relat Disord. 2019 Apr;61:26-33. doi: 10.1016/j.parkreldis.2018.11.013. Epub 2018 Nov 15. Review.

PMID:
30470656
14.

Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers.

Soria JA, Huisa BN, Edland SD, Litvan I, Peavy GM, Salmon DP, Hansen LA, Galasko DR, Brewer JB, González HM, Rissman RA.

J Alzheimers Dis. 2018;66(4):1539-1548. doi: 10.3233/JAD-180789.

PMID:
30412501
15.

Altered Functional Interactions of Inhibition Regions in Cognitively Normal Parkinson's Disease.

Harrington DL, Shen Q, Theilmann RJ, Castillo GN, Litvan I, Filoteo JV, Huang M, Lee RR.

Front Aging Neurosci. 2018 Oct 23;10:331. doi: 10.3389/fnagi.2018.00331. eCollection 2018.

16.

Progress in the treatment of Parkinson-Plus syndromes.

Olfati N, Shoeibi A, Litvan I.

Parkinsonism Relat Disord. 2019 Feb;59:101-110. doi: 10.1016/j.parkreldis.2018.10.006. Epub 2018 Oct 3.

PMID:
30314846
17.

Prominent tongue and jaw tremor in a patient with probable Progressive Supranuclear Palsy.

Shoeibi A, Litvan I.

Mov Disord Clin Pract. 2018 Jan-Feb;5(1):99-100. doi: 10.1002/mdc3.12562. Epub 2017 Oct 23. No abstract available.

18.

Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.

Moreno GM, Gandhi R, Lessig SL, Wright B, Litvan I, Nahab FB.

Neurology. 2018 Oct 23;91(17):797-799. doi: 10.1212/WNL.0000000000006396. Epub 2018 Sep 26. No abstract available.

19.

Does the Geriatric Depression Scale measure depression in Parkinson's disease?

Lopez FV, Split M, Filoteo JV, Litvan I, Moore RC, Pirogovsky-Turk E, Liu L, Lessig S, Schiehser DM.

Int J Geriatr Psychiatry. 2018 Dec;33(12):1662-1670. doi: 10.1002/gps.4970. Epub 2018 Sep 25.

PMID:
30251374
20.

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.

Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D; IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2018 Nov;33(11):1750-1759. doi: 10.1002/mds.110. Epub 2018 Sep 14.

PMID:
30216541
21.

Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson's disease.

Bluett B, Banks S, Cordes D, Bayram E, Mishra V, Cummings J, Litvan I.

Alzheimers Dement (N Y). 2018 Jun 13;4:387-394. doi: 10.1016/j.trci.2018.04.010. eCollection 2018.

22.

Movement disorder society criteria for clinically established early Parkinson's disease.

Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schäffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB.

Mov Disord. 2018 Oct;33(10):1643-1646. doi: 10.1002/mds.27431. Epub 2018 Aug 25.

PMID:
30145841
23.

Validation of the MDS clinical diagnostic criteria for Parkinson's disease.

Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, Halliday G, Goetz CG, Chan P, Slow E, Seppi K, Schaffer E, Rios-Romenets S, Mi T, Maetzler C, Li Y, Heim B, Bledsoe IO, Berg D.

Mov Disord. 2018 Oct;33(10):1601-1608. doi: 10.1002/mds.27362. Epub 2018 Aug 25.

PMID:
30145797
24.

Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress.

Yuan SH, Hiramatsu N, Liu Q, Sun XV, Lenh D, Chan P, Chiang K, Koo EH, Kao AW, Litvan I, Lin JH.

Hum Mol Genet. 2018 Nov 15;27(22):3951-3963. doi: 10.1093/hmg/ddy297.

25.

Cognition among individuals along a spectrum of increased risk for Parkinson's disease.

Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D; Parkinson’s Progression Markers Initiative.

PLoS One. 2018 Aug 20;13(8):e0201964. doi: 10.1371/journal.pone.0201964. eCollection 2018.

26.

Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative.

Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC.

Neurodegener Dis. 2018;18(4):173-190. doi: 10.1159/000488780. Epub 2018 Aug 8.

27.

Traumatic Brain Injury and Firearm Use and Risk of Progressive Supranuclear Palsy Among Veterans.

Kelley KD, Checkoway H, Hall DA, Reich SG, Cunningham C, Litvan I.

Front Neurol. 2018 Jun 20;9:474. doi: 10.3389/fneur.2018.00474. eCollection 2018.

28.

Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype.

Koga S, Kouri N, Walton RL, Ebbert MTW, Josephs KA, Litvan I, Graff-Radford N, Ahlskog JE, Uitti RJ, van Gerpen JA, Boeve BF, Parks A, Ross OA, Dickson DW.

Acta Neuropathol. 2018 Sep;136(3):389-404. doi: 10.1007/s00401-018-1878-z. Epub 2018 Jun 20.

29.

Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy.

Shoeibi A, Olfati N, Litvan I.

Expert Opin Investig Drugs. 2018 Apr;27(4):349-361. doi: 10.1080/13543784.2018.1460356. Epub 2018 Apr 9. Review.

30.

Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.

Litvan I, Kieburtz K, Tröster AI, Aarsland D.

Mov Disord. 2018 Apr;33(4):520-527. doi: 10.1002/mds.27345. Epub 2018 Mar 24. Review.

PMID:
29573469
31.

Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.

Goldman JG, Holden SK, Litvan I, McKeith I, Stebbins GT, Taylor JP.

Mov Disord. 2018 Apr;33(4):503-510. doi: 10.1002/mds.27323. Epub 2018 Feb 28. Review.

PMID:
29488270
32.

Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.

Park HK, Ilango S, Charriez CM, Checkoway H, Riley D, Standaert DG, Bordelon Y, Shprecher DR, Reich SG, Hall D, Kluger B, Marras C, Jankovic J, Dubinsky R, Litvan I; ENGENE-PSP Study.

Mov Disord. 2018 Mar;33(3):468-472. doi: 10.1002/mds.27336. Epub 2018 Feb 20.

33.

At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease.

Weintraub D, Hamilton JL, Eberling J, Litvan I.

Mov Disord. 2018 Apr;33(4):501-502. doi: 10.1002/mds.27310. Epub 2018 Feb 8. No abstract available.

PMID:
29418018
34.

Anti-inflammatory drug use and progressive supranuclear palsy.

Marras C, Cunningham CR, Hou J, Proudfoot J, Standaert DG, Juncos J, Riley D, Reich SG, Hall D, Kluger B, Bordelon Y, Shprecher DR, Litvan I; for ENGENE-PSP.

Parkinsonism Relat Disord. 2018 Mar;48:89-92. doi: 10.1016/j.parkreldis.2017.11.346. Epub 2017 Dec 6.

PMID:
29307562
35.

Fall Prediction and Prevention Systems: Recent Trends, Challenges, and Future Research Directions.

Rajagopalan R, Litvan I, Jung TP.

Sensors (Basel). 2017 Nov 1;17(11). pii: E2509. doi: 10.3390/s17112509. Review.

36.

Genetic influences on cognition in progressive supranuclear palsy.

Gerstenecker A, Roberson ED, Schellenberg GD, Standaert DG, Shprecher DR, Kluger BM, Litvan I.

Mov Disord. 2017 Dec;32(12):1764-1771. doi: 10.1002/mds.27196. Epub 2017 Oct 27.

37.

18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.

Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous MD Sr, Tsai R, Winer J, Russell DS, Litvan I, Roberson ED, Seeley WW, Grinberg LT, Kramer JH, Miller BL, Pressman P, Nasrallah I, Baker SL, Gomperts SN, Johnson KA, Grossman M, Jagust WJ, Boxer AL, Rabinovici GD.

Ann Neurol. 2017 Oct;82(4):622-634. doi: 10.1002/ana.25060.

38.

Aberrant Intrinsic Activity and Connectivity in Cognitively Normal Parkinson's Disease.

Harrington DL, Shen Q, Castillo GN, Filoteo JV, Litvan I, Takahashi C, French C.

Front Aging Neurosci. 2017 Jun 19;9:197. doi: 10.3389/fnagi.2017.00197. eCollection 2017.

39.

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU.

Lancet Neurol. 2017 Jul;16(7):552-563. doi: 10.1016/S1474-4422(17)30157-6. Epub 2017 Jun 13. Review.

40.

Mild cognitive impairment as a risk factor for Parkinson's disease dementia.

Hoogland J, Boel JA, de Bie RMA, Geskus RB, Schmand BA, Dalrymple-Alford JC, Marras C, Adler CH, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ; MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2017 Jul;32(7):1056-1065. doi: 10.1002/mds.27002. Epub 2017 Jun 12.

41.

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease.

Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D; Parkinson’s Progression Markers Initiative (PPMI).

PLoS One. 2017 May 17;12(5):e0175674. doi: 10.1371/journal.pone.0175674. eCollection 2017.

42.

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):995-1005. doi: 10.1002/mds.27034. Epub 2017 May 13. Review.

43.

Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, van Eimeren T, Golbe LI, Kassubek J, Kurz C, Litvan I, Pantelyat A, Rabinovici G, Respondek G, Rominger A, Rowe JB, Stamelou M, Josephs KA; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):955-971. doi: 10.1002/mds.27038. Epub 2017 May 13. Review.

44.

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.

45.

Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease.

Holiday KA, Pirogovsky-Turk E, Malcarne VL, Filoteo JV, Litvan I, Lessig SL, Song D, Schiehser DM.

Mov Disord Clin Pract. 2017 Sep-Oct;4(5):717-723. doi: 10.1002/mdc3.12479. Epub 2017 Mar 16.

46.

The Role of Stress as a Risk Factor for Progressive Supranuclear Palsy.

Kelley KD, Peavy G, Edland S, Rogers W, Riley DE, Bordelon Y, Standaert D, Reich SG, Litvan I.

J Parkinsons Dis. 2017;7(2):377-383. doi: 10.3233/JPD-160945.

47.

Levodopa-Responsive Parkinsonism Associated with Giant Virchow-Robin Spaces: A Case Report.

Shoeibi A, Litvan I.

Mov Disord Clin Pract. 2017 Mar 27;4(4):619-622. doi: 10.1002/mdc3.12484. eCollection 2017 Jul-Aug. No abstract available.

48.

Understanding falls in progressive supranuclear palsy.

Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J; ENGENE PSP study.

Parkinsonism Relat Disord. 2017 Feb;35:75-81. doi: 10.1016/j.parkreldis.2016.12.009. Epub 2016 Dec 15.

PMID:
28007518
49.

Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study.

Pirogovsky-Turk E, Moore RC, Filoteo JV, Litvan I, Song DD, Lessig SL, Schiehser DM.

Am J Geriatr Psychiatry. 2017 Mar;25(3):279-289. doi: 10.1016/j.jagp.2016.10.004. Epub 2016 Oct 12.

PMID:
27838315
50.

Progression of brain atrophy in PSP and CBS over 6 months and 1 year.

Dutt S, Binney RJ, Heuer HW, Luong P, Attygalle S, Bhatt P, Marx GA, Elofson J, Tartaglia MC, Litvan I, McGinnis SM, Dickerson BC, Kornak J, Waltzman D, Voltarelli L, Schuff N, Rabinovici GD, Kramer JH, Jack CR Jr, Miller BL, Rosen HJ, Boxer AL; AL-108-231 investigators.

Neurology. 2016 Nov 8;87(19):2016-2025. Epub 2016 Oct 14.

Supplemental Content

Loading ...
Support Center